A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
A legfontosabb adatok
- Ki végzi
- ModernaTX, Inc.
- Hol
- Decatur, Hialeah, Hollywood, Houston, Lenexa, Marlton, Miami, Philadelphia, River Forest, San Antonio, Sugar Land és Tomball (Egyesült Államok)Mind a 12 helyszín megnézéseMég 1 másik országban, 4 helyszínen
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 2. fázis
- Résztvevők
- 931 fő vett részt
- Kezdés
- 2024. júl. 15.
- Befejezés
- 2025. szept. 25.
- A vizsgálat típusa
- Beavatkozással járó, 6 csoport
- A vizsgált kezelések
- mRNA-1083
- A regiszteradat frissítve
- 2026. október 8.
Ki vehet részt
- Életkor
- 50 év – 64 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Investigator assessment that the participant understands and is willing and physically able to comply with protocol-mandated follow-up, including all procedures
- Participants of nonchildbearing potential may be enrolled in the study
- Participants who could become pregnant: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
- Have received an influenza vaccine in the previous season (since September 2023 for Part 1, since Sep 2024 for Part 2)
Ki nem vehet részt
- Received corticosteroids at ≥10 milligrams (mg)/day of prednisone or equivalent for >14 days in total within 90 days prior to Day 1 or is anticipating the need for corticosteroids at any time during the study
- Received systemic immunosuppressive treatment, including long-acting biological therapies that affect immune responses (e.g., infliximab), within 180 days prior to Day 1 or plans to do so during the study
- Received or plans to receive any vaccine authorized or approved by a local health agency within 28 days prior to Day 1 or plans to do so within 28 days post study injection
- Received a licensed seasonal influenza vaccine within 150 days prior to Day 1
- Received a licensed/authorized SARS-CoV-2 vaccine within 90 days prior to Day 1
- Received any investigational influenza vaccine, investigational coronavirus disease 2019 (COVID-19) vaccine, or investigational combination vaccine for influenza and COVID-19 within 12 months prior to Day 1. Participants from mRNA-1083-P201 Part 1 will also be excluded from Part 2; Other protocol-defined inclusion/exclusion criteria may apply
- Reported diagnosis or condition that is associated with increased risk of severe influenza disease or complications, including individuals with chronic medical conditions
- Reported history of congenital or acquired immunodeficiency, immunosuppressive condition, asplenia, or recurrent severe infections
- History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any of the following: mRNA vaccine or therapeutic; components of an mRNA vaccine or therapeutic; influenza vaccine; or components of an influenza vaccine, including egg protein
Helyszínek itt: Egyesült Államok
Még 1 másik országban, 4 helyszínen
- Cenexel IRADecatur, Egyesült Államok
- Indago Research & Health Center, IncHialeah, Egyesült Államok
- CenExel RCAHollywood, Egyesült Államok
- DM Clinical Research - Cyfair Clinical Research Center - PPDSHouston, Egyesült Államok
- JCCTLenexa, Egyesült Államok
- Hassman Research Institute - Berlin - CenExel - PPDSMarlton, Egyesült Államok
- Suncoast Research Group, LLC dba Flourish ResearchMiami, Egyesült Államok
- DM Clinical Research - PhiladelphiaPhiladelphia, Egyesült Államok
- DM Clinical Research - River ForestRiver Forest, Egyesült Államok
- Clinical Trials of Texas, LLC., dba Flourish ResearchSan Antonio, Egyesült Államok
- DM Clinical Research - SugarlandSugar Land, Egyesült Államok
- DM Clinical Research - Tomball MDCTomball, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to <65 years of age.
A vizsgálat 6 csoportja
- Part 1 Group 1 - mRNA-1083 Lot AA vizsgált kezelés
Participants will receive mRNA-1083 Lot A as a single injection on Day 1 in Part 1.
Kezelés: mRNA-1083
- Part 1 Group 2 - mRNA-1083 Lot BA vizsgált kezelés
Participants will receive mRNA-1083 Lot B as a single injection on Day 1 in Part 1.
Kezelés: mRNA-1083
- Part 1 Group 3 - mRNA-1083 Lot CA vizsgált kezelés
Participants will receive mRNA-1083 Lot C as a single injection on Day 1 in Part 1.
Kezelés: mRNA-1083
- Part 1 Group 4 - mRNA-1083 Lot DA vizsgált kezelés
Participants will receive mRNA-1083 Lot D as a single injection on Day 1 in Part 1.
Kezelés: mRNA-1083
- Part 2 Group 5 - mRNA-1083 Lot AA vizsgált kezelés
Participants will receive mRNA-1083 Lot A as a single injection on Day 1 in Part 2.
Kezelés: mRNA-1083
- Part 2 Group 6 - mRNA-1083 Lot EA vizsgált kezelés
Participants will receive mRNA-1083 Lot E as a single injection on Day 1 in Part 2.
Kezelés: mRNA-1083
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity in Relation to the Product Attributes of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Adults ≥50 to <65 Years of Age
- A regiszteradat frissítve
- 2026. október 8.